Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inhibikase Therapeutics ( (IKT) ) has provided an announcement.
Inhibikase Therapeutics entered an At the Market Offering Agreement with H.C. Wainwright & Co. to sell shares of its common stock up to $5.66 million. They sold 315,338 shares for $849,187.85 but later reduced the sale limit to $50,000 and ultimately terminated the agreement effective December 11, 2024. This move reflects strategic adjustments in their stock offering endeavors.
For an in-depth examination of IKT stock, go to TipRanks’ Stock Analysis page.